These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 26253364)

  • 1. Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States.
    Schaefer CP; Cappelleri JC; Cheng R; Cole JC; Guenthner S; Fowler J; Johnson S; Mamolo C
    J Am Acad Dermatol; 2015 Oct; 73(4):585-593.e3. PubMed ID: 26253364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis.
    D'Souza LS; Payette MJ
    J Am Acad Dermatol; 2015 Apr; 72(4):589-98. PubMed ID: 25631851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study.
    Feldman SR; Zhao Y; Gilloteau I; Graham CN; Miles L; McBride D; Herrera V
    J Manag Care Spec Pharm; 2018 Jul; 24(7):617-622. PubMed ID: 29952701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.
    Fonia A; Jackson K; Lereun C; Grant DM; Barker JN; Smith CH
    Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden of moderate to severe plaque psoriasis in Canada.
    Levy AR; Davie AM; Brazier NC; Jivraj F; Albrecht LE; Gratton D; Lynde CW
    Int J Dermatol; 2012 Dec; 51(12):1432-40. PubMed ID: 23171010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost-effectiveness analysis comparing methotrexate with PUVA therapy for moderate-severe psoriasis in the sanitary area of Badajoz].
    de Argila D; Rodríguez-Nevado I; Chaves A
    Actas Dermosifiliogr; 2007; 98(1):35-41. PubMed ID: 17374331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study.
    Schöffski O; Augustin M; Prinz J; Rauner K; Schubert E; Sohn S; Reich K
    J Dtsch Dermatol Ges; 2007 Mar; 5(3):209-18. PubMed ID: 17338796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age U.S. adults.
    Chandran A; Schaefer C; Ryan K; Baik R; McNett M; Zlateva G
    J Manag Care Pharm; 2012; 18(6):415-26. PubMed ID: 22839682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional study.
    Ghatnekar O; Ljungberg A; Wirestrand LE; Svensson A
    Eur J Dermatol; 2012; 22(2):238-45. PubMed ID: 22361745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A higher score on the dermatology life quality index, being on systemic treatment and having a diagnosis of psoriatic arthritis is associated with increased costs in patients with plaque psoriasis.
    Ekelund M; Mallbris L; Qvitzau S; Stenberg B
    Acta Derm Venereol; 2013 Nov; 93(6):684-8. PubMed ID: 23603935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
    Feldman SR; Evans C; Russell MW
    J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine.
    Opmeer BC; Heydendael VM; De Borgie CA; Spuls PI; Bossuyt PM; Bos JD; De Rie MA
    Arch Dermatol; 2004 Jun; 140(6):685-90. PubMed ID: 15210458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of psoriasis on health care costs and patient work loss.
    Fowler JF; Duh MS; Rovba L; Buteau S; Pinheiro L; Lobo F; Sung J; Doyle JJ; Swensen A; Mallett DA; Kosicki G
    J Am Acad Dermatol; 2008 Nov; 59(5):772-80. PubMed ID: 19119095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health status, function, productivity, and costs among individuals with idiopathic painful peripheral neuropathy with small fiber involvement in the United States: results from a retrospective chart review and cross-sectional survey.
    Schaefer C; Mann R; Sadosky A; Daniel S; Parsons B; Nalamachu S; Stacey BR; Tuchman M; Anschel A; Nieshoff E
    J Med Econ; 2014 Jun; 17(6):394-407. PubMed ID: 24673364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical and cost-effectiveness of psoralen + ultraviolet A versus psoralen + sunlight in the treatment of chronic plaque psoriasis in a developing economy.
    Aggarwal K; Khandpur S; Khanna N; Sharma VK; Pandav CS
    Int J Dermatol; 2013 Apr; 52(4):478-85. PubMed ID: 23431966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom.
    Warren RB; Halliday A; Graham CN; Gilloteau I; Miles L; McBride D
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2178-2184. PubMed ID: 29846965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the economic burden of psoriasis in the United States.
    Vanderpuye-Orgle J; Zhao Y; Lu J; Shrestha A; Sexton A; Seabury S; Lebwohl M
    J Am Acad Dermatol; 2015 Jun; 72(6):961-7.e5. PubMed ID: 25882886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study.
    Sohn S; Schoeffski O; Prinz J; Reich K; Schubert E; Waldorf K; Augustin M
    Dermatology; 2006; 212(2):137-44. PubMed ID: 16484820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.
    Pan F; Brazier NC; Shear NH; Jivraj F; Schenkel B; Brown R
    Value Health; 2011; 14(5):652-6. PubMed ID: 21839402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managed care aspects of psoriasis and psoriatic arthritis.
    Evans C
    Am J Manag Care; 2016 Jun; 22(8 Suppl):s238-43. PubMed ID: 27356195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.